1. Home
  2. TSBX

TSBX

Turnstone Biologics Corp.

Logo Turnstone Biologics Corp.

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Founded: 2015 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 62.6M IPO Year: 2023
Target Price: $19.00 AVG Volume (30 days): 200.7K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -4.78 EPS Growth: N/A
52 Week Low/High: $1.63 - $13.20 Next Earning Date: 05-11-2024
Revenue: $19,306,000 Revenue Growth: -73.66%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: